• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sanofi

    3/31/21 11:19:51 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    SC 13G 1 d166797dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

     

    LAVA Therapeutics N.V.1

    (Name of Issuer)

    Common Shares, €0.12 par value

    (Title of Class of Securities)

    N51517105

    (CUSIP Number)

    March 25, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    1 

    Per the 424(b) Prospectus dated March 24, 2021: “Prior to the closing of this offering, we will complete a corporate reorganization in the course of which we will be converted into a public company under Dutch law (naamloze vennootschap) and our legal name will change to LAVA Therapeutics N.V. Therefore, investors in this offering will only acquire, and this prospectus only describes the offering of, common shares of LAVA Therapeutics N.V.”

     

     

     


    CUSIP No. N51517105

     

     

      1.    

      Names of Reporting Persons

     

      SANOFI

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      The Republic of France

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      1,919,455 shares

       6.   

      Shared Voting Power

     

      0 share

       7.   

      Sole Dispositive Power

     

      1,919,455 shares

       8.   

      Shared Dispositive Power

     

      0 share

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,919,455 shares

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

    7.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    2


    Item 1.
       (a)    Name of Issuer
    LAVA Therapeutics N.V.
       (b)    Address of Issuer’s Principal Executive Offices
    Yalelaan 60, 3584 CM Utrecht, The Netherlands
    Item 2.
       (a)    Name of Person Filing
    Sanofi
       (b)    Address of Principal Business Office or, if none, Residence
    54 Rue La Boétie, 75008 Paris (France)
       (c)    Citizenship
    The Republic of France
       (d)    Title of Class of Securities
    Common Shares, €0.12 par value
       (e)    CUSIP Number
    N51517105
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

     

      

    (k)

      

    ☐

      

    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

    § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    3


    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)   

    Amount beneficially owned:

    1,919,455 shares

       (b)   

    Percent of class:

    7.0%

       (c)    Number of shares as to which the person has:
          (i)   

    Sole power to vote or to direct the vote

    1,919,455 shares

          (ii)   

    Shared power to vote or to direct the vote

    0 share

          (iii)   

    Sole power to dispose or to direct the disposition of

    1,919,455 shares

          (iv)   

    Shared power to dispose or to direct the disposition of

    0 share

    Item 5.    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person

    Sanofi Foreign Participations B.V.                1,919,455 shares                7.0%

    *The shares are held of record by Sanofi Foreign Participations B.V., the reporting person’s indirect, wholly-owned subsidiary.

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    Not applicable.
    Item 8.    Identification and Classification of Members of the Group
    Not applicable.

     

    4


    Item 9.    Notice of Dissolution of Group
    Not applicable.
    Item 10.    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    March 31, 2021

    Date

    /s/ Alexandra Roger*

    Signature

    Alexandra Roger

    Head of Securities Law and Capital Markets

    Name/Title

     

    *

    Alexandra Roger is signing on behalf of Sanofi by power of attorney previously filed with the Securities and Exchange Commission on February 3, 2016 as Exhibit 24 to Form 4, and hereby incorporated by reference herein.

     

    6

    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Sanofi with a new price target

      Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00

      3/21/25 8:12:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi upgraded by Deutsche Bank

      Deutsche Bank upgraded Sanofi from Sell to Hold

      1/30/25 3:33:45 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

      Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA

      4/21/25 4:05:00 PM ET
      $DVAX
      $MRNA
      $SNY
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

      Teigen to advocate for the importance of type 1 diabetes screening after son's diagnosis was uncovered during an unexpected medical emergencyScreen For Type 1 movement continues momentum into year two with the goal of encouraging people to screen early; just one blood test can spot type 1 diabetes before symptoms occurMORRISTOWN, N.J., April 15, 2025 /PRNewswire/ -- Sanofi, a leader in diabetes care, welcomes author, entrepreneur, and mom Chrissy Teigen as its new celebrity spokesperson for the Screen For Type 1 movement. The partnership, announced on T1D Day, comes as the Screen For Type 1 movement strives to expand diabetes education nationwide, raising awareness of the benefits of early r

      4/15/25 8:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season

      BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. Sanofi plans to begin shipping flu vaccines this summer so that health systems, hospitals, pharm

      3/14/25 2:18:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SNY
    SEC Filings

    See more

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sanofi

      SC 13G/A - Sanofi (0001121404) (Subject)

      11/7/24 2:49:36 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sanofi

      SC 13G - Sanofi (0001121404) (Filed by)

      5/31/24 4:30:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sanofi (Amendment)

      SC 13G/A - Sanofi (0001121404) (Subject)

      2/14/24 3:57:49 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Sanofi

      13F-HR - Sanofi (0001121404) (Filer)

      5/6/25 6:15:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      5/5/25 1:12:12 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      4/30/25 2:50:47 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

      4 - Sanofi (0001121404) (Reporting)

      8/2/21 8:34:24 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by Sanofi

      3 - Sanofi (0001121404) (Reporting)

      7/28/21 8:32:04 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Bridging the Gap between the Homeless and Society via Futsal

      Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

      10/17/23 9:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

      BRIDGEWATER, N.J., Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses. Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of Sanofi France, will lead the business unit responsible for serving the Diabetes, Cardiovascular and Transplant communities effective September 1. Bogillot joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. In March 2020, he was appointed President of Sanofi France, where he has led

      8/3/22 2:53:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Financials

    Live finance-specific insights

    See more
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

      ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, toda

      5/13/24 7:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

      ― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate developments, in conjunction with the first quarter 2024 financial results ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a c

      5/13/24 6:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

      Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P

      5/10/24 2:15:00 AM ET
      $NVAX
      $SNY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations